Straight Shot with Dr. Clete Barrick

Let Dr. Barrick know what you think of the episode and send any questions his way too!

There are now two FDA-approved GLP-1 pills for weight loss, and they are not the same drug. Dr. Clete Barrick (board-certified in internal medicine and obesity medicine) breaks down the side-by-side: the chemistry, the dosing rules, the weight loss data, the side effects, the cost, and which patient profile fits each pill.

What you'll learn:
- Why Foundayo (orforglipron) and oral Wegovy (semaglutide 25 mg) are pharmacologically different drugs, not just two brands of the same thing
- The morning ritual oral Wegovy requires and why pharmacokinetic studies say you can't cheat it
- Trial weight loss numbers from ATTAIN-1 (Foundayo) and OASIS 4 (oral Wegovy) and what the 1.2-point gap actually means in real life
- The side effect paradox: lower nausea on Foundayo but higher discontinuation at the top dose
- May 2026 self-pay and insured pricing through LillyDirect and NovoCare
- The patient profiles where each pill is the right answer, and the case where a needle is still better than a pill

Timestamps:
0:00 — Opening
0:45 — Welcome to Straight Shot
1:00 — Why this matters now
2:30 — Shot 1: The chemistry
4:45 — Shot 2: How you take each pill
7:00 — Shot 3: How much weight comes off
9:15 — Shot 4: The side effect paradox
11:30 — GLP-1 Bible pre-order
12:00 — Shot 5: What you'll actually pay
13:00 — The Straight Shot
14:30 — Wrap & subscribe

Studies and sources referenced:
- Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). NEJM. 2025;393(18):1796-1806.
- Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4). NEJM. 2025;393(11):1077-1087.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). NEJM. 2021;384(11):989-1002.
- Buckley ST et al. Transcellular stomach absorption of a derivatized GLP-1 receptor agonist. Sci Transl Med. 2018;10(467):eaar7047.
- Granhall C et al. Safety and pharmacokinetics of single and multiple ascending doses of oral semaglutide. Clin Pharmacokinet. 2019;58(6):781-791.
- Foundayo (orforglipron) Prescribing Information. Eli Lilly. April 2026.
- Wegovy (semaglutide tablets) Prescribing Information. Novo Nordisk. December 2025.
- Eli Lilly. ATTAIN-MAINTAIN press release, December 18, 2025.
- LillyDirect Foundayo pricing, April 2026.
- NovoCare Wegovy pricing, April 2026.

Resources:
- Pre-order The GLP-1 Bible: barrickhealth.com
- Book a 1-on-1 consult with Dr. Barrick: barrickhealth.com
- YouTube: @BarrickHealth
- Reddit: u/CleteBarrickMD

Disclaimer: This episode is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting, stopping, or changing any medication.

Let Dr. Barrick know what you think of the episode and send any questions his way too!

A new study in Nature Health used AI to scan over 400,000 Reddit posts from 67,000 GLP-1 users and uncovered side effects that aren't on the label. Fox News, CNN, and Medscape ran the same headline: "hidden side effects doctors are missing."

Dr. Clete Barrick, board-certified in internal medicine and obesity medicine, prescribes these medications every day and takes tirzepatide himself. In this episode, he walks through what the University of Pennsylvania researchers actually found, why the methodology matters, and where every headline got it wrong.

You'll hear the truth about the 13% psychiatric symptom finding, why menstrual changes and cold sensitivity aren't "hidden" at all, and the real story buried under the clickbait: the system for catching side effects is broken. Includes counter-data from The Lancet Psychiatry and Nature Medicine showing GLP-1s are associated with lower mental health risk, not higher.

If you want a physician who actually monitors all of this, book a free consult at barrickhealth.com. Subscribe for weekly evidence-based GLP-1 content from a doctor who's been on the medication.

YouTube: youtube.com/@BarrickHealth

Let Dr. Barrick know what you think of the episode and send any questions his way too!

Semaglutide or tirzepatide? Ozempic or Mounjaro? It's the most asked question in GLP-1 medicine, and Dr. Clete Barrick has prescribed both to over 5,000 patients.

In this episode, he covers the real differences between single and dual agonist medications, the head-to-head SURMOUNT-5 trial results, side effect profiles (including the birth control interaction most providers miss), who actually does better on which medication, and why the best GLP-1 is the one you can afford to stay on.

He also addresses compounding costs, why semaglutide is sometimes the smarter pick despite tirzepatide's stronger averages, the oral Wegovy option for patients with needle phobia, and the fear-mongering around FDA regulatory moves that's driving patients to make bad decisions.

In this episode:

• Single vs. dual agonist: what the mechanism difference actually means
• SURMOUNT-5 and the 2026 Bernardi meta-analysis (28 trials, 34,000 patients)
• Why averages hide a massive spread in individual responses
• GI side effects compared (and why tirzepatide is often better tolerated)
• The birth control absorption warning (59% reduction with tirzepatide)
• Autoimmune conditions, migraines, and PCOS: which medication has the edge
• Compounding costs: semaglutide vs. tirzepatide pricing reality
• The sledgehammer vs. Michelangelo analogy
• Why you shouldn't switch medications based on social media fear

New episodes weekly. Subscribe and visit barrickhealth.com for physician-led GLP-1 care.

Everything discussed in this episode is education, not medical advice for your specific situation. Talk to your prescriber before making changes to your treatment.

LINKS: barrickhealth.com https://www.youtube.com/@BarrickHealth

REFERENCES CITED:

• Jastreboff AM, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025.
• Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
• Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
• Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.
• Bernardi S, et al. Network meta-analysis of tirzepatide vs semaglutide (28 RCTs, 34,367 patients). J Diabetes. 2026.
• Mounjaro prescribing information: oral contraceptive absorption interaction data.

Let Dr. Barrick know what you think of the episode and send any questions his way too!

Your body already makes GLP-1 every time you eat. The problem? Natural GLP-1 lasts about two minutes before an enzyme destroys it. Semaglutide and tirzepatide are engineered to do the same job, just louder and longer.

Dr. Clete Barrick breaks down how these medications work at three job sites: your pancreas, your stomach, and (most importantly) your brain. He explains the difference between homeostatic hunger and hedonic hunger, why GLP-1s quiet "food noise" through the brain's reward circuit, and why the "you only lose weight because you feel sick" myth is flat wrong.

In this episode:

• GLP-1: the hormone you already make
• Three job sites: pancreas, stomach, brain
• Homeostatic vs. hedonic hunger (the car wash sign analogy)
• Why less than 1% of weight loss comes from nausea
• Semaglutide vs. tirzepatide: what's different
• What GLP-1s don't do
• The Straight Shot: you are not cheating

No biochemistry degree required. Just the science you need to understand what's happening when you take your shot.

New episodes weekly. Subscribe and visit barrickhealth.com for physician-led weight loss care.

Let Dr. Barrick know what you think of the episode and send any questions his way too!

Dr. Clete Barrick is dual board-certified in internal medicine and obesity medicine, has treated thousands of GLP-1 patients going on five years, and has personally lost over 80 pounds on tirzepatide. In this premiere episode of Straight Shot, he tells the full story: how a Navy physician couldn't outrun his own biology, what changed when the food noise went quiet, and why he built this show.

He also breaks down the problem he sees every day: patients being mismanaged on GLP-1s by providers running one size fits all algorithms without understanding the clinical nuance. Patients told they're "maxed out" who have options nobody mentioned. Patients who think the medication failed when the care is what failed.

In this episode:

• Dr. Barrick's 80+ lbs. weight loss story on tirzepatide
• What "food noise" is and what it feels like when it stops
• Lessons from treating thousands of GLP-1 patients
• The Kevin story: told he was "maxed out," lost another 9%
• Why access to GLP-1s without expertise is failing patients
• What to expect from future episodes of Straight Shot

This is the show where an obesity medicine doctor who takes the medication himself gives you the information your doctor doesn't have time to explain. No hedging. No corporate script. Just the straight shot.

New episodes weekly. Visit barrickhealth.com for physician-led weight loss care.